<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39393523</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Impact of Early Antiviral Therapy on SARS-CoV-2 Clearance Time in High-Risk COVID-19 subjects: A Propensity Score Matching Study.</ArticleTitle><Pagination><StartPage>107265</StartPage><MedlinePgn>107265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2024.107265</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(24)00336-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Effective treatments for COVID-19 are needed to mitigate disease progression and reduce the burden on healthcare systems. This study investigates the impact of early treatments on SARS-CoV-2 viral shedding duration among high-risk individuals with mild symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A single-centre, retrospective observational study was conducted at Luigi Sacco Hospital in Milan from December 2021 to March 2023. Hospitalized and non-hospitalized adults with a confirmed SARS-CoV-2 infection and at high-risk of disease progression were enrolled. Unadjusted and adjusted negative binomial regression models and a Random Forest regression model were performed before and after matching subjects based on their propensity of being treated or not.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results from 518 subjects (428 treated and 90 untreated) revealed a significant reduction in SARS-CoV-2 viral shedding duration among those who received early treatment compared to untreated individuals. Propensity score matching and multivariable regression analyses confirmed this finding. Early treatment significantly reduced the risk of COVID-19-related hospitalization and pneumonia development. Subgroup analysis identified COPD as a potential factor influencing effectiveness of early treatments.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early treatments play a crucial role in reducing SARS-CoV-2 viral shedding and preventing disease progression among high-risk individuals. Shorter viral shedding duration also contributes to improved healthcare resource utilization and infection control measures.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colaneri</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Immunopathology, Department of Clinical Sciences, University of Milan, Luigi Sacco Hospital, Milan, Italy.; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fama</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Immunopathology, Department of Clinical Sciences, University of Milan, Luigi Sacco Hospital, Milan, Italy.; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.. Electronic address: federico.fama@unimi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fassio</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Public Health, Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Darcy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Infectious Disease Unit Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scaglione</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Immunopathology, Department of Clinical Sciences, University of Milan, Luigi Sacco Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Immunopathology, Department of Clinical Sciences, University of Milan, Luigi Sacco Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galli</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Immunopathology, Department of Clinical Sciences, University of Milan, Luigi Sacco Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antinori</LastName><ForeName>Spinello</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.; III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gori</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Immunopathology, Department of Clinical Sciences, University of Milan, Luigi Sacco Hospital, Milan, Italy.; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.; III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Agostino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.; Infectious Diseases Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiavini</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Immunopathology, Department of Clinical Sciences, University of Milan, Luigi Sacco Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Ospedale Luigi Sacco “COVID-19 Hotspot” study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COPD</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">early treatments</Keyword><Keyword MajorTopicYN="N">high-risk subjects</Keyword><Keyword MajorTopicYN="N">time to negativization</Keyword><Keyword MajorTopicYN="N">viral shedding</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>13</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>13</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39393523</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2024.107265</ArticleId><ArticleId IdType="pii">S1201-9712(24)00336-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>